Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Does metformin usage improve survival in head and neck squamous cell carcinoma? A population-based study.

Quimby AE, Lebo NL, Griffiths R, Hall S, Dimitroulakos J, Johnson-Obaseki S.

J Otolaryngol Head Neck Surg. 2018 Dec 4;47(1):74. doi: 10.1186/s40463-018-0322-7.

2.

C-reactive Protein in HPV-Positive and HPV-Negative Oropharyngeal Cancer.

Johnson-Obaseki S, Caulley L, Corsten M, Liu G, Dimitroulakos J, Goldstein D, Irish J, Rider J.

Otolaryngol Head Neck Surg. 2018 Sep 18:194599818800297. doi: 10.1177/0194599818800297. [Epub ahead of print]

PMID:
30226795
3.

Correction to: HPV DNA in saliva from patients with SCC of the head and neck is specific for p16-positive oropharyngeal tumours.

Wasserman JK, Rourke R, Purgina B, Caulley L, Dimitroulakos J, Corsten M, Johnson-Obaseki S.

J Otolaryngol Head Neck Surg. 2018 Aug 2;47(1):49. doi: 10.1186/s40463-018-0294-7.

4.

Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells.

Sulaiman A, McGarry S, Lam KM, El-Sahli S, Chambers J, Kaczmarek S, Li L, Addison C, Dimitroulakos J, Arnaout A, Nessim C, Yao Z, Ji G, Song H, Liu S, Xie Y, Gadde S, Li X, Wang L.

Cell Death Dis. 2018 Jul 26;9(8):815. doi: 10.1038/s41419-018-0811-7.

5.

Activating Transcription Factor 3 as a Novel Regulator of Chemotherapy Response in Breast Cancer.

Hasim MS, Nessim C, Villeneuve PJ, Vanderhyden BC, Dimitroulakos J.

Transl Oncol. 2018 Aug;11(4):988-998. doi: 10.1016/j.tranon.2018.06.001. Epub 2018 Jun 22.

6.

Effect of statin use on oncologic outcomes in head and neck squamous cell carcinoma.

Lebo NL, Griffiths R, Hall S, Dimitroulakos J, Johnson-Obaseki S.

Head Neck. 2018 Aug;40(8):1697-1706. doi: 10.1002/hed.25152. Epub 2018 Jun 22.

PMID:
29934959
7.

Human papillomavirus: An unlikely etiologic factor in sinonasal inverted papilloma.

Mohajeri S, Lai C, Purgina B, Almutairi D, Baghai T, Dimitroulakos J, Kilty S.

Laryngoscope. 2018 Nov;128(11):2443-2447. doi: 10.1002/lary.27207. Epub 2018 Apr 18.

PMID:
29668071
8.

Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.

Sulaiman A, McGarry S, Li L, Jia D, Ooi S, Addison C, Dimitroulakos J, Arnaout A, Nessim C, Yao Z, Ji G, Song H, Gadde S, Li X, Wang L.

Mol Oncol. 2018 Apr;12(4):423-440. doi: 10.1002/1878-0261.12167. Epub 2018 Feb 21.

9.

Customized Viral Immunotherapy for HPV-Associated Cancer.

Atherton MJ, Stephenson KB, Pol J, Wang F, Lefebvre C, Stojdl DF, Nikota JK, Dvorkin-Gheva A, Nguyen A, Chen L, Johnson-Obaseki S, Villeneuve PJ, Diallo JS, Dimitroulakos J, Wan Y, Lichty BD.

Cancer Immunol Res. 2017 Oct;5(10):847-859. doi: 10.1158/2326-6066.CIR-17-0102. Epub 2017 Sep 14.

10.

Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3.

Weberpals JI, Lo B, Duciaume MM, Spaans JN, Clancy AA, Dimitroulakos J, Goss GD, Sekhon HS.

Clin Cancer Res. 2017 Aug 1;23(15):4501-4510. doi: 10.1158/1078-0432.CCR-16-3230. Epub 2017 Apr 4.

11.

Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ERα coinhibition.

Sulaiman A, Sulaiman B, Khouri L, McGarry S, Nessim C, Arnaout A, Li X, Addison C, Dimitroulakos J, Wang L.

FEBS Lett. 2016 Dec;590(24):4606-4616. doi: 10.1002/1873-3468.12496. Epub 2016 Dec 9.

12.

Assessment of Circulating LncRNAs Under Physiologic and Pathologic Conditions in Humans Reveals Potential Limitations as Biomarkers.

Schlosser K, Hanson J, Villeneuve PJ, Dimitroulakos J, McIntyre L, Pilote L, Stewart DJ.

Sci Rep. 2016 Nov 18;6:36596. doi: 10.1038/srep36596.

13.

Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non-Small Cell Lung Carcinoma Cells.

Bar J, Hasim MS, Baghai T, Niknejad N, Perkins TJ, Stewart DJ, Sekhon HS, Villeneuve PJ, Dimitroulakos J.

Neoplasia. 2016 Sep;18(9):525-35. doi: 10.1016/j.neo.2016.07.004.

14.

A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies.

Goss GD, Jonker DJ, Laurie SA, Weberpals JI, Oza AM, Spaans JN, la Porte C, Dimitroulakos J.

J Transl Med. 2016 Mar 31;14:83. doi: 10.1186/s12967-016-0836-6.

15.

Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.

Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.

PLoS One. 2016 Mar 10;11(3):e0150567. doi: 10.1371/journal.pone.0150567. eCollection 2016.

16.

Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.

Bar J, Ding K, Zhao H, Han L, Laurie SA, Seymour L, Addison CL, Shepherd FA, Goss GD, Dimitroulakos J, Bradbury PA.

Clin Lung Cancer. 2015 Nov;16(6):e189-201. doi: 10.1016/j.cllc.2015.05.002. Epub 2015 May 13.

PMID:
26081815
17.

miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.

Bar J, Gorn-Hondermann I, Moretto P, Perkins TJ, Niknejad N, Stewart DJ, Goss GD, Dimitroulakos J.

Clin Lung Cancer. 2015 Nov;16(6):e121-9. doi: 10.1016/j.cllc.2015.01.008. Epub 2015 Feb 3.

PMID:
25703099
18.

Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.

Dayekh K, Johnson-Obaseki S, Corsten M, Villeneuve PJ, Sekhon HS, Weberpals JI, Dimitroulakos J.

Mol Cancer Ther. 2014 Nov;13(11):2559-71. doi: 10.1158/1535-7163.MCT-13-1086. Epub 2014 Sep 4.

19.

miR-105 inhibits prostate tumour growth by suppressing CDK6 levels.

Honeywell DR, Cabrita MA, Zhao H, Dimitroulakos J, Addison CL.

PLoS One. 2013 Aug 7;8(8):e70515. doi: 10.1371/journal.pone.0070515. eCollection 2013.

20.

Lovastatin-induced apoptosis is mediated by activating transcription factor 3 and enhanced in combination with salubrinal.

Niknejad N, Gorn-Hondermann I, Ma L, Zahr S, Johnson-Obeseki S, Corsten M, Dimitroulakos J.

Int J Cancer. 2014 Jan 15;134(2):268-79. doi: 10.1002/ijc.28369. Epub 2013 Aug 1.

21.

Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells.

Ma L, Niknejad N, Gorn-Hondermann I, Dayekh K, Dimitroulakos J.

PLoS One. 2012;7(9):e46055. doi: 10.1371/journal.pone.0046055. Epub 2012 Sep 28.

22.

Enhancement of cisplatin cytotoxicity by disulfiram involves activating transcription factor 3.

O'Brien A, Barber JE, Reid S, Niknejad N, Dimitroulakos J.

Anticancer Res. 2012 Jul;32(7):2679-88.

PMID:
22753726
23.

Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.

Le Boeuf F, Niknejad N, Wang J, Auer R, Weberpals JI, Bell JC, Dimitroulakos J.

Int J Cancer. 2012 Aug 1;131(3):E204-15. doi: 10.1002/ijc.27404. Epub 2012 Jan 11.

24.

Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease.

Vickers MM, Bar J, Gorn-Hondermann I, Yarom N, Daneshmand M, Hanson JE, Addison CL, Asmis TR, Jonker DJ, Maroun J, Lorimer IA, Goss GD, Dimitroulakos J.

Clin Exp Metastasis. 2012 Feb;29(2):123-32. doi: 10.1007/s10585-011-9435-3. Epub 2011 Nov 26.

PMID:
22120473
25.

The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells.

Weberpals JI, O'Brien AM, Niknejad N, Garbuio KD, Clark-Knowles KV, Dimitroulakos J.

Cancer Cell Int. 2011 Aug 19;11(1):29. doi: 10.1186/1475-2867-11-29.

26.

Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors.

Zhao TT, Trinh D, Addison CL, Dimitroulakos J.

PLoS One. 2010 Sep 3;5(9):e12563. doi: 10.1371/journal.pone.0012563.

27.
28.

Lovastatin induces neuronal differentiation and apoptosis of embryonal carcinoma and neuroblastoma cells: enhanced differentiation and apoptosis in combination with dbcAMP.

Arnold DE, Gagne C, Niknejad N, McBurney MW, Dimitroulakos J.

Mol Cell Biochem. 2010 Dec;345(1-2):1-11. doi: 10.1007/s11010-010-0553-z. Epub 2010 Aug 9.

PMID:
20694854
29.

Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3.

St Germain C, Niknejad N, Ma L, Garbuio K, Hai T, Dimitroulakos J.

Neoplasia. 2010 Jul;12(7):527-38.

30.

Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins.

Zhao TT, Le Francois BG, Goss G, Ding K, Bradbury PA, Dimitroulakos J.

Oncogene. 2010 Aug 19;29(33):4682-92. doi: 10.1038/onc.2010.219. Epub 2010 Jun 21.

PMID:
20562912
31.

The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer.

Weberpals J, Garbuio K, O'Brien A, Clark-Knowles K, Doucette S, Antoniouk O, Goss G, Dimitroulakos J.

Int J Cancer. 2009 Feb 15;124(4):806-15. doi: 10.1002/ijc.23987.

32.

Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.

Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos J.

J Neurooncol. 2008 Oct;90(1):9-17. doi: 10.1007/s11060-008-9627-0. Epub 2008 Jun 20.

PMID:
18566746
33.

Activation of the integrated stress response regulates lovastatin-induced apoptosis.

Niknejad N, Morley M, Dimitroulakos J.

J Biol Chem. 2007 Oct 12;282(41):29748-56. Epub 2007 Aug 14.

34.

Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway.

Dimitroulakos J, Lorimer IA, Goss G.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4426s-4431s. Review.

35.

Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.

Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA, Dimitroulakos J.

Clin Cancer Res. 2005 Mar 15;11(6):2398-407.

36.

A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix.

Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, Moore MJ, Chin S, Irish J, LaFramboise S, Oza AM.

Eur J Cancer. 2005 Mar;41(4):523-30. Epub 2005 Jan 22.

PMID:
15737556
37.

Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells.

Mantha AJ, McFee KE, Niknejad N, Goss G, Lorimer IA, Dimitroulakos J.

J Cancer Res Clin Oncol. 2003 Nov;129(11):631-41. Epub 2003 Aug 26.

PMID:
12942316
38.

Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.

Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, Kamel-Reid S.

Neoplasia. 2002 Jul-Aug;4(4):337-46.

39.

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis.

Wong WW, Dimitroulakos J, Minden MD, Penn LZ.

Leukemia. 2002 Apr;16(4):508-19. Review.

40.

Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.

Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ.

Leukemia. 2001 Sep;15(9):1398-407.

PMID:
11516100
41.

Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.

Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn LZ.

Clin Cancer Res. 2001 Jul;7(7):2067-75.

42.

Lovastatin induces a pronounced differentiation response in acute myeloid leukemias.

Dimitroulakos J, Thai S, Wasfy GH, Hedley DW, Minden MD, Penn LZ.

Leuk Lymphoma. 2000 Dec;40(1-2):167-78.

PMID:
11426618
43.

Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia.

Minden MD, Dimitroulakos J, Nohynek D, Penn LZ.

Leuk Lymphoma. 2001 Feb;40(5-6):659-62.

PMID:
11426537
44.

Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.

Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH, Yeger H, Penn LZ.

Clin Cancer Res. 2001 Jan;7(1):158-67.

45.

Co-localization of patched and activated sonic hedgehog to lysosomes in neurons.

Mastronardi FG, Dimitroulakos J, Kamel-Reid S, Manoukian AS.

Neuroreport. 2000 Feb 28;11(3):581-5.

PMID:
10718318
46.

Identification of a novel zinc finger gene, zf5-3, as a potential mediator of neuroblastoma differentiation.

Dimitroulakos J, Pienkowska M, Sun P, Farooq S, Zielenska M, Squire JA, Yeger H.

Int J Cancer. 1999 Jun 11;81(6):970-8.

47.

Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro.

Macaulay RJ, Wang W, Dimitroulakos J, Becker LE, Yeger H.

J Neurooncol. 1999 Mar;42(1):1-11.

PMID:
10360474
48.

Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach.

Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH, Minden MD, Penn LZ.

Blood. 1999 Feb 15;93(4):1308-18.

49.

MYCN protein expression as a predictor of neuroblastoma prognosis.

Chan HS, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J, Yeger H, Ling V.

Clin Cancer Res. 1997 Oct;3(10):1699-706.

50.

Selection of probes for fluorescence in situ hybridization analysis by differential display polymerase chain reaction of mRNA from rhabdomyosarcoma.

Pienkowska M, Dimitroulakos J, Zielenska M, Thorner P, Plavsic N, Yeger H, Squire JA.

Cancer Genet Cytogenet. 1996 Nov;92(1):58-65.

PMID:
8956874

Supplemental Content

Loading ...
Support Center